Bocxman,
Thanks for your post. I have studied it carefully. I have always learned by sharing thoughts with others. I would appreciate it, if you would give your thoughts on the following, some of which is taken from the July 8, 2005 Research Notes :
Only a few well-established cancer markers are routinely used by physicians, including AFP (liver cancer), CEA (colorectal cancer), PSA (prostate cancer) and Ca125 (ovarian cancer). Other markers are not specific enough or are not elevated early enough in the disease process. Consequently, a large number of tests (like blood counts, biopsy, spinal taps, lymphangiograms, ultrasounds, bone scans, x-rays, CAT scans, MRI's and surgery) are currently used for cancer diagnosis. For instance, a Total PSA of 4 triggers a prostate biopsy. A number less than 4 doesn't. The goal being to screen for and diagnose cancer early when it is most treatable. If I am reading things correctly, BOCX is stating that the overall sensitivity of Serum-RECAF is over 90% with 95% specificity using a drop of blood, and this potentially translates to earlier cancer detection. If RECAF is sensitive enough to detect cancer early, (although not the specific kind of cancer or location), and some of the various tests mentioned above, like CAT scans, currently have to be done regardless, why not have a stand alone RECAF test done routinely, just for the possible early detection of cancer somewhere in the body? Those other tests, like CAT scans, then are used to locate the cancer. Thanks, kag
